Abstract | BACKGROUND: METHODS: RESULTS: During a median follow-up period of 3.7 years, the primary end point occurred in 769 of 7924 patients (9.7%) in the darapladib group and 819 of 7904 patients (10.4%) in the placebo group (hazard ratio in the darapladib group, 0.94; 95% confidence interval [CI], 0.85 to 1.03; P=0.20). There were also no significant between-group differences in the rates of the individual components of the primary end point or in all-cause mortality. Darapladib, as compared with placebo, reduced the rate of major coronary events (9.3% vs. 10.3%; hazard ratio, 0.90; 95% CI, 0.82 to 1.00; P=0.045) and total coronary events (14.6% vs. 16.1%; hazard ratio, 0.91; 95% CI, 0.84 to 0.98; P=0.02). CONCLUSIONS:
|
Authors | STABILITY Investigators, Harvey D White, Claes Held, Ralph Stewart, Elizabeth Tarka, Rebekkah Brown, Richard Y Davies, Andrzej Budaj, Robert A Harrington, P Gabriel Steg, Diego Ardissino, Paul W Armstrong, Alvaro Avezum, Philip E Aylward, Alfonso Bryce, Hong Chen, Ming-Fong Chen, Ramon Corbalan, Anthony J Dalby, Nicolas Danchin, Robbert J De Winter, Stefan Denchev, Rafael Diaz, Moses Elisaf, Marcus D Flather, Assen R Goudev, Christopher B Granger, Liliana Grinfeld, Judith S Hochman, Steen Husted, Hyo-Soo Kim, Wolfgang Koenig, Ales Linhart, Eva Lonn, José López-Sendón, Athanasios J Manolis, Emile R Mohler 3rd, José C Nicolau, Prem Pais, Alexander Parkhomenko, Terje R Pedersen, Daniel Pella, Marco A Ramos-Corrales, Mikhail Ruda, Mátyás Sereg, Saulat Siddique, Peter Sinnaeve, Peter Smith, Piyamitr Sritara, Henk P Swart, Rody G Sy, Tamio Teramoto, Hung-Fat Tse, David Watson, W Douglas Weaver, Robert Weiss, Margus Viigimaa, Dragos Vinereanu, Junren Zhu, Christopher P Cannon, Lars Wallentin |
Journal | The New England journal of medicine
(N Engl J Med)
Vol. 370
Issue 18
Pg. 1702-11
(May 01 2014)
ISSN: 1533-4406 [Electronic] United States |
PMID | 24678955
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Benzaldehydes
- Oximes
- Phospholipase A2 Inhibitors
- darapladib
|
Topics |
- Aged
- Benzaldehydes
(administration & dosage, adverse effects)
- Coronary Artery Disease
(complications, drug therapy)
- Coronary Disease
(drug therapy, mortality)
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Myocardial Infarction
(prevention & control)
- Oximes
(administration & dosage, adverse effects)
- Phospholipase A2 Inhibitors
(administration & dosage, adverse effects)
- Stroke
(prevention & control)
- Treatment Failure
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|